The Bioscience Association of Maine strongly opposes LD 1422, “An Act To Allow Maine Residents To Personally Import Medications as Permitted under the Federal Food, Drug, and Cosmetic Act”. This legislation, if passed, will present a great risk to the public health of Maine residents and will also open the State of Maine to additional costly and unnecessary litigation. BAM is of the opinion that the legislation outlined in LD 1422 is misguided and we feel inappropriately addresses the issue it purportedly seeks to remedy. Read full statement here
Related Posts
Bar Harbor approves Jackson Lab’s $33M expansion for rare disease research
The Bar Harbor Planning Board has approved a plan by the Jackson Laboratory to build a 20,000-square-foot expansion to its Rare Disease Translational...
Bigelow lab receives $7 million for algae research, business development
Researchers at Bigelow Laboratory for Ocean Sciences believe algae can make a big splash in the agricultural, aquaculture and pharmaceutical industries,...
Should Maine create a public medical school? UMaine System will study the question
The University of Maine System said this week it will work with a national consultant to study the feasibility of launching the state’s...